In contrast, RIPK1 degraders employ the ubiquitin-proteasome system to completely clear RIPK1, simultaneously ablating scaffold-mediated survival signals and relieving inhibition on the RIPK3-MLKL pathway, significantly enhancing anti-tumour immunity. The gene discussed is MLKL; the disease is neoplasm.